Head-to-head · Cost-Efficiency Index
PepHaūs vs Hims & Hers
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
PepHaūs
People who want a verified all-50 program with both molecules disclosed and will pay mid-market for the peace of mind.
Visit PepHaūsHims & Hers
People who want a familiar, app-driven consumer brand and only need semaglutide.
Visit Hims & HersThe verdict
PepHaūs takes it, leading the Cost-Efficiency Index 85 to 83. Mid-market $152/$246 pricing on both molecules, all-50 and LegitScript-verified — a clean, verified nationwide option that trades rock-bottom cost for a dependable pharmacy. Hims & Hers still earns a B — People who want a familiar, app-driven consumer brand and only need semaglutide.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs PepHaūs.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | PepHaūs | Hims & Hers |
|---|---|---|
| Cost-Efficiency Index | 85/100 | 83/100 |
| Semaglutide / mo | $152/mo | $199/mo |
| Tirzepatide / mo | $246/mo | Not disclosed |
| Semaglutide / yr (modeled) | $1,824 | $2,388 |
| Tirzepatide / yr (modeled) | $2,952 | — |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #18 | #22 |
PepHaūs
85/100Where the value is
- Both molecules disclosed at flat prices with nationwide all-50 access
- LegitScript-certified pharmacy behind the program
- Predictable pricing that's straightforward to model for a year
The tradeoffs
- $152/$246 is mid-market — undercut on raw cost by several verified all-50 rivals
- Compounded only — no brand-name or oral option
Hims & Hers
83/100Where the value is
- Nationwide
- Slick app experience
- Semaglutide priced up front for modeling
The tradeoffs
- Tirzepatide pricing not consistently disclosed
- Compounded supply has drawn industry-wide regulatory scrutiny
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hims in September 2025. We still list and link to Hims & Hers; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.